Public Release: 

Future vaccine may help lower blood pressure long-term

American Heart Association Rapid Access Journal Report

American Heart Association

DALLAS, May 26, 2015 - A vaccine may one day help lower blood pressure for up to six months, according to new research in the American Heart Association's journal Hypertension.

The study in rats may eventually provide a novel alternative to treat high blood pressure in people, who would not need to take a pill everyday.

"The potential of a vaccine for hypertension offers an innovative treatment that could be very effective for the control of non-compliance which is one of the major problems in the management of hypertensive patients," said Hironori Nakagami M.D., Ph.D., study co-author and professor at Osaka University in Japan.

Researchers have designed a DNA vaccine that targets angiotensin II ? a hormone that raises blood pressure by causing blood vessels to constrict. This narrowing can increase your blood pressure and force your heart to work harder.

In the study, researchers immunized hypertensive rats three times at two-week intervals with needleless injections. The vaccine not only lowered blood pressure for up to six months, but also reduced tissue damage to the heart and blood vessels associated with hypertension. There were no signs of damage to other organs such as the kidney or liver.

The DNA vaccine works similar to common ACE inhibitor blood pressure medications which help blood vessels relax and open up, which, in turn, lowers blood pressure. Other types of vaccines have been tested for hypertension (e.g. a peptide vaccine), but didn't have lasting effects and some had undesirable side effects.

The ultimate goal of an anti-hypertensive vaccine is to achieve perfect blood pressure control by improving drug compliance through the vaccine. In addition, in the developing countries like Africa and south Asia, anti-hypertensive drugs such as ARB (angiotensin receptor blockade) are expensive. A DNA vaccine may provide cheaper and effective anti-hypertensive treatments in such countries, researchers said.

"Further research on this DNA vaccine platform, including increasing the longevity of blood pressure reduction, may eventually provide a new therapeutic option to treat hypertensive patients," Nakagami said.

The technology can also be applied to generate other vaccines.


Co-authors are Hiroshi Koriyama M.D., Ph.D; Futoshi Nakagami; M.D., Ph.D; Mariana Kiomy Osako, Ph.D; Mariko Kyutoku, Ph.D; Munehisa Shimamura M.D.; Ph.D; Hitomi Kurinami M.D., Ph.D; Tomohiro Katsuya M.D., Ph.D; Hiromi Rakugi M.D., Ph.D; and Ryuichi Morishita M.D., Ph.D. Author disclosures are on the manuscript.

Additional Resources:

  • Learn about high blood pressure
  • Follow AHA/ASA news on Twitter @HeartNews.
  • For the updates and new science from the Hypertension journal follow @HyperAHA.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.